WHA52.19 - Revised Drug Strategy. WHA Resolution; Fifty-second World Health Assembly, 1999
(1999; 3 pages) [Arabic] [Chinese] [French] [Russian] [Spanish]

Abstract

REQUESTS the Director-General:

  1. to support Member States in their efforts to develop and implement policies and programmes that achieve the objectives of the revised drug strategy, including the development of tools, guidelines and methodology for evaluation and monitoring;
  2. to adopt a comprehensive strategy to implement the WHO Ethical Criteria for Medicinal Drug Promotion and to continue to review its effectiveness with all interested parties;
  3. to extend the guidelines incorporated in the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce to cover pharmaceutical starting materials; to develop and disseminate uniform guidelines on the regulatory control, export, import and transit conditions of pharmaceutical products; and to develop standards of practice for entities involved i n international trade in pharmaceuticals and pharmaceutical starting materials;
  4. to establish and develop a model inspection certificate for the national inspection of pharmaceutical manufacturing sites of starting materials and finished pharmaceutical products in order to ensure compliance with WHO Good Manufacturing Practices, and to collaborate with Member States, at their request, in implementation;
  5. to strengthen and expand the provision of independent information on market prices of starting materials of assured quality for production of essential drugs;
  6. to continue the development and dissemination, also using electronic media such as the Internet, of independent information on safety of pharmaceutical products and instances of counterfeit drugs or medicines, on drug selection and on rational prescribing;
  7. to cooperate with Member States, at their request, and with international organizations in monitoring and analysing the pharmaceutical and public health implications of relevant international agreements, including trade agreements, so that Member States can effectively assess and subsequently develop pharmaceutical and health policies and regulatory measures that address their concerns and priorities, and are able to maximize the positive and mitigate the negative impact of those agreements;
  8. to review and update the revised drug strategy to reflect current and continued challenges in the pharmaceutical sector and the principles articulated in the renewed health-for-all policy;
  9. to report to the Fifty-third World Health Assembly on progress achieved and problems encountered in the implementation and renewal of WHO’s revised drug strategy, with recommendations for action.
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014